Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
BACKGROUND
: The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS).


METHODS
: Mifepristone (RU-486; 200 mg orally) was given daily to patients with progesterone receptor-positive advanced or recurrent endometrioid adenocarcinoma or LGESS. Patients were evaluated every 4 weeks for toxicity and response. Quality-of-life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy.


RESULTS
: Twelve of 13 enrolled patients were evaluable in the first phase of accrual. Stable disease was noted in 3 of 12 patients (at 8 weeks, 12 weeks, and > or =77 weeks, respectively), and the median time to disease progression was 48 days. Among the patients who had stable disease, 2 women had endometrioid endometrial cancer, and 1 woman had LGESS. No partial or complete responses were observed. The most frequent grade 1 and 2 toxicities were anorexia, fatigue, and mood alterations observed in 50%, 50%, and 58% of patients, respectively. The most common grade 3 toxicities were fatigue and dyspnea observed in 25% and 17% of patients, respectively. One patient experienced grade 4 dyspnea. Thirty-three percent of patients had asymptomatic elevations of corticotropin. No serious treatment-related adverse events occurred. There were no significant changes in quality of life.


CONCLUSIONS
: Single-agent mifepristone used in the treatment of recurrent endometrioid adenocarcinoma or LGESS resulted in a stable disease rate of 25%. One patient who had a biopsy-positive disease recurrence remained stable at 77 weeks. Although mifepristone was tolerated well, as a single agent, it provided limited response as a single agent in women with progesterone receptor-positive uterine tumors. Recently, was been recognized that biologic agents used as single agents may result only in stable disease unless they are combined with cytotoxic agents. The authors concluded that further research into the best mode of application for mifepristone in the treatment of endometrial cancer is needed. Cancer 2009. (c) 2009 American Cancer Society.
Ramondetta
Lois M
LM
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Johnson
Alaina J
AJ
Sun
Charlotte C
CC
Atkinson
Neely
N
Smith
Judith A
JA
Jung
Maria S
MS
Broaddus
Russel
R
Iyer
Revathy B
RB
Burke
Thomas
T
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000188:drug therapy*; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D015735:Mifepristone / Q000627:therapeutic use*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011980:Receptors, Progesterone / Q000378:metabolism; D012008:Recurrence; D018203:Sarcoma, Endometrial Stromal / Q000188:drug therapy*
D006727:Hormone Antagonists; D011980:Receptors, Progesterone; D015735:Mifepristone